Stereotaxis (company)
| Company type | Public |
|---|---|
| AMEX: STXS | |
| Industry | Medical appliances and equipment |
| Headquarters | |
Key people | David L. Fischel (CEO) |
| Products | Robotic Magnetic Navigation Systems Genesis RMN System GenesisX RMN MAGiC EMAGIN Map-iT |
| Website | www |
Stereotaxis Inc. is an American publicly traded medical technology company based in St. Louis, Missouri, that makes robotic systems used by physicians to perform minimally-invasive endovascular procedures, including electrophysiology studies and cardiac catheter ablation procedures.
Products
[edit]The Niobe Magnetic Navigation System includes two pods that use permanent magnets mounted on pivoting arms and positioned on opposing sides of the operating table.[1] The magnets are controlled by physicians from the outside using[2] a mouse, keyboard, joystick, and[3] a viewing screen. The rotation of the magnets within the Niobe pods influences the magnetic catheters in the heart to make micro movements of the catheter tip (in increments of 1 mm to 9 mm) to navigate throughout the four chambers of the heart.[4][5][1][6]
The RMN system was originally designed for applications within the brain; its current usage is guiding magnetic catheters during electrophysiology studies and catheter ablation procedures to treat arrhythmias in the heart.[7] It has been used in over 100,000 procedures worldwide as of 2017.[8] In January 2022, Stereotaxis announced that the Fuwai Central China Cardiovascular Hospital became the first in central China to establish a robotic electrophysiology program with the product.[9] In January 2025, Stereotaxis announced the first order for its GenesisX endovascular surgical robotics system [10] and announced European CE mark approval of its proprietary robotically-navigated magnetic ablation catheter.[11] In March 2025, Stereotaxis filed for FDA approval of a magnetically navigated endovascular guide-catheter and a magnetically navigated high density mapping catheter.[12] In July 2025 that magnetic mapping catheter received FDA approval.[13] In November 2025 Stereotaxis' GenesisX endovascular surgical robotics system was approved by the FDA.[14]
References
[edit]- ^ a b "Niobe® system". Stereotaxis. Retrieved November 16, 2017.
- ^ "AccessGUDID - DEVICE: Navigant (M588020004500260)". accessgudid.nlm.nih.gov. Retrieved November 16, 2017.
- ^ "AccessGUDID - DEVICE: Odyssey (M58800100701020)". accessgudid.nlm.nih.gov. Retrieved November 16, 2017.
- ^ "Magnetic vs Manual Catheters". Stereotaxis. Retrieved November 16, 2017.
- ^ "Odyssey® solution". Stereotaxis. Retrieved November 16, 2017.
- ^ Yuan, Shiwen; Holmqvist, Fredrik; Kongstad, Ole; Jensen, Steen M.; Wang, Lingwei; Ljungström, Erik; Hertervig, Eva; Borgquist, Rasmus (November 2, 2017). "Long-term outcomes of the current remote magnetic catheter navigation technique for ablation of atrial fibrillation". Scandinavian Cardiovascular Journal. 51 (6): 308–315. doi:10.1080/14017431.2017.1384566. ISSN 1401-7431. PMID 28958165. S2CID 25501499.
- ^ "AccessGUDID - DEVICE: Niobe MNS Philips (M58800100610010)". accessgudid.nlm.nih.gov. Retrieved November 16, 2017.
- ^ "Stereotaxis' (STXS) CEO David Fischel on Q1 2017 Results - Earnings Call Transcript". www.msn.com. Retrieved November 16, 2017.
- ^ "Fuwai Central China Cardiovascular Hospital Adopts Stereotaxis Robotic Magnetic Navigation Technology". Surgical Robotics Technology. January 28, 2022. Retrieved January 31, 2022.
- ^ https://www.massdevice.com/stereotaxis-has-first-order-for-its-next-gen-surgical-robot/
- ^ https://www.massdevice.com/stereotaxis-magic-ablation-catheter-is-now-ce-mark-approved/
- ^ https://www.therobotreport.com/stereotaxis-submits-catheter-pair-fda-clearance/
- ^ https://www.massdevice.com/fda-clears-stereotaxis-ep-mapping-catheter/
- ^ https://www.medtechdive.com/news/Stereotaxis-GenesisX-surgical-robot-FDA-clearance/805267/